Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum wcfs1
- Development stage
- Preclinical
- Lead developer
- Wageningen University & Research
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum WCFS1, previously known as Lactobacillus plantarum WCFS1, is a specific probiotic strain of bacteria originally isolated from human saliva. [1, 3, 14] It is one of the most well-characterized probiotic strains, being the first Lactobacillus species to have its entire genome sequenced in 2003. [1, 10] Due to its robustness and high survival rate through the gastrointestinal tract, it has been extensively studied for its potential health benefits. [1, 12] Clinical and preclinical research suggests it may modulate the host's immune system and improve intestinal barrier function. [2, 11] It is widely used in functional genomics research as a model organism for lactic acid bacteria and has been explored for various applications, from functional foods to a potential delivery vehicle for therapeutic compounds. [1, 14, 16]
- Other names
- Lactobacillus plantarum WCFS1
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on lactiplantibacillus plantarum wcfs1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum wcfs1.